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Salivary gland cancer — epidemiology
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Salivary gland tumors represent 3–11% of all head and neck cancers and 0.2% of all neoplasms. Among Poles, mali-
gnancies involving the large salivary glands constituted 0.3% of all malignancies in Poland and 9.7% of head and neck 
neoplasms. In 2014, the morbidity rate was higher among women, but over the past 15 years there has been a slight 
prevalence among men. As for benign neoplasms in Poland, the most commonly seen are pleomorphic adenoma 
and Warthin’s tumor. Cystic glandular cancer, mucoid epidermal carcinoma and adenocarcinoma are among the 
most frequent malignancies. Less common are lymphoma and squamous cell carcinoma. Salivary gland neoplasms 
are usually located in the parotid gland, then in the sub-mandibular gland. The best prognosis is for women whose 
cancers are located in the parotid gland and those with lobular carcinoma. Figures have been on the rise lately, ho-
wever. Deaths have been on a stable level.
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Introduction 
Salivary gland cancers are rare, constituting 3–11% of 
all head and neck neoplasms and 0.2% of all malignancies, 
depending on the author [1–3]. Most occur in the sixth 
decade of life [4]. The proportional morbidity for men and 
women is similar with men to women ratio being 1.3 : 1 [4]. 
This type of cancer develops both in large (parotid, sub-
-mandibular sublingual) as well as in small salivary glands 
located within the mucous membrane of the upper section 
of the gastrointestinal tract. Salivary gland cancers are a very 
non-homogenous group, in which 32 histological types and 
subtypes can be distinguished [5]. Therefore, the epide-
miology of these neoplasms is not well recognized. Many 
studies include only data on parotid gland cancer, others 
contain data concerning only the large salivary glands. As 
a relatively large number of neoplasms are benign lesions, 
epidemiological data are incomplete and can in many ca-
ses be underestimated. Additionally, because of the rarity 
of incidence and great diversity of those neoplasms, data 
concerning the etiology of specific histopathological types 
are scant. In this paper, we present the latest epidemiological 
data concerning salivary gland neoplasms.
Epidemiology of salivary gland neoplasms 
globally and in Europe
Data concerning the world population are incomplete. 
Malignant neoplasms of salivary glands are extremely rare, 
the figures range from 0.05–2/100,000 inhabitants. The hi-
ghest number of new cases come from Croatia, where there 
are 1.8/100,000 new cases of this type of cancer found in 
men [6]. The highest number of salivary gland cancers are 
found in the European and North American population. 
Compared with Africa, the proportion is 40:6, whereas for 
Asia it is 40:1 [4]. Studies on the US population show a gro-
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wing tendency in the last few years. The number of new 
cases per 100,000 had grown in 1974–1999 from 0.1% to 
1.1%. Of all head and neck cancers, this number was 6.3 in 
the years 1974–1976 while in the years 1998–1999 it was 
8.3%. Analysis of the SEER (Surveillance, Epidemiology, and 
End Results) database points to a statistically significant 
fall in cases with locally contained disease (56.0% – 44.9%; 
p < 0.004) and a statistically insignificant increase in cases 
with locally advanced and disseminated disease (27.0% 
– 31.2%; p = 0.060 and from 10.4% to 15.6%; p = 0.859) 
[2]. For many years, the percentage of 5-year survival has 
been stable at 68%, but the percentage of survival in locally 
advanced stages has improved slightly (83.7% – 88.5%; 
p = 0.012) [2]. 
Studies of the European database, RARECARE (Surveil-
lance of Rare Cancers in Europe) from 1995–2002 indicate 
that the largest percentage of new cases is among the elder-
ly > 65 years of age — 1.42/100,000, and among the middle 
aged from 25–64 years of age — 0.42/100,000. Salivary gland 
cancers slightly prevail among men (0.45/100,000) compa-
red with women (0.32/100,000) [7]. The largest number of 
new cases is reported for West- (0.45/100,000) and Central 
Europeans (0.42/100,000). The fewest new cases are repor-
ted for Eastern European countries (0.32/100,000) [7]. Data 
from the EUROCARE-4 study [8], for the years 1995–1999 
point to a 1.3 five-year survival rate at 83, 69, 65% respecti-
vely with male survival at 58% and female survival at 59%. 
The survival rate was falling with age and was 87% among 
patients aged 15–47 and 59 among patients over 74 years 
of age [8]. EUROCARE-5 data point to slightly worse survival. 
In 1999–2007, the percentage of 5-year survivals was 58% 
[9]. Similar results come from the RARECARE study [7]. The 
percentage rate of 1- and 5-year survival of patients treated 
in 2000–2005 in all Europe was 87% and 71% respectively. 
Among women it was higher and was 91 and 81% respec-
tively. To compare, 1- and 5-year survival in men was 84 and 
62% respectively. Younger patients had better prognoses. 
Among patients aged 25–64, 1- and 5-year survival was 
91% and 74% respectively, and among older patients it 
was 82 and 64%. The highest survival rate was reported 
for Western Europe — 1- and 5-year survival there was 90 
and 81% respectively. The lowest 1- and 5-year survival 
rate was reported for Eastern Europe and was 74 and 52% 
respectively [7]. 
Morbidity and death rate in Poland 
The Polish National Cancer Registry (KRN) allows analysis 
of morbidity and death incidence only in large gland mali-
gnancies. Data concerning small salivary gland neoplasms, 
due to common coding with other histopathological forms 
in specific anatomic locations, are incomplete. Similarly, 
data concerning non-malignant morbidity are unavailable. 
The analysis of KRN (10) data shows that in 2014 there were 
478 new cases of large salivary gland cancer, of which 372 
cases (78%) were located in the parotid gland. In Poland, 
large salivary gland neoplasms constituted 0.3% of all ma-
lignancies and 9.7% — of head and neck neoplasms [10]. 
The raw factor for parotid gland morbidity was 0.97 and for 
the sub-mandibular and sub-lingual salivary gland — 0.28. 
Factors standardized with respect to the European popula-
tion, for the parotid and the other salivary glands, 0.78 and 
0.23 respectively, and those standardized for the global 
population were 0.57 and 0.16 respectively [10].
In 2014, 221 new cases of salivary gland neoplasms were 
found in men, of which 168 cases concerned the parotid 
gland (76%). Salivary gland neoplasms constituted 0.27% 
of all malignancies and 8.5% — of head and neck neopla-
sms. In 2014, there were 257 new cases of salivary gland 
neoplasms, of which 203 cases concerned the parotid gland 
(76%) [10]. Salivary gland neoplasms constituted 0.32% 
of all neoplasms and 20.8% of head and neck cancers. In 
2010–2014, among the male population, men who contrac-
ted the disease were those aged 85+ (the raw factor 7.75 was 
for the parotid gland and 1.2 — for the rest of the salivary 
glands). Similarly, among women the majority of new cases 
of salivary gland cancer in the recent years of 2010–2014 
concerned patients over after 85 years of age (the raw factor 
2.5 was for the parotid gland and 1.23 for the remaining 
salivary glands) [10]. Population studies in laryngological 
care units point to the highest morbidity in the 50–65 age 
bracket, which probably results from the highest percentage 
of patients qualifying for surgery in this age group and not 
from the real number of patients [1, 14, 20].
With the parotid gland, the highest morbidity was in 
2014, reported in the Carpathian Province (raw factor 5.54, 
118 new cases of salivary gland cancer). The lowest morbi-
dity was noted in Lesser Poland Province (raw factor 0.36, 
12 new cases) [10]. The highest number of new cases con-
cerning other salivary gland neoplasms was reported in 
Podlasie Province (raw factor 0.48, 12 cases) and the lowest 
— in Lesser Poland Province (raw factor 0,15, 5 cases) [10]. 
Over the last 10 years, the most malignancies of the parotid 
gland were noted in the Carpathian Province and of other 
salivary glands neoplasms in Lodz Province. The fewest new 
cases of parotid gland neoplasms were in Warmia-Masuria 
Province and of other salivary gland neoplasms in Podlasie 
Province (Fig. 1) [10].
In 2014, 230 patients died of salivary gland cancer (169 
of parotid gland cancer, 51 of other salivary gland neopla-
sms). The raw factor for deaths was 0.44 for parotid gland 
and 0.16 for other salivary gland malignancies [10]. Deaths 
due to salivary gland neoplasms were 0.24% of all deaths 
caused by malignancy and 8.5 of deaths caused by head 
and neck malignancy. Among men in 2014, there were 134 
deaths, of which 98 concerned the parotid gland (73%), 
0.53 — the parotid gland and 0.19 some other malignancy. 
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Salivary gland malignancies constituted 0.25% of deaths 
due to all malignancies and 6.7% of deaths caused by head 
and neck malignancy. Among women there were 96 deaths 
in 2014, of which in 71 cases the cause was the parotid 
gland cancer (74%). The raw factor was 0.36 for the parotid 
gland and 0.13 for the salivary gland neoplasms. Salivary 
gland neoplasms constituted 0.22% of deaths among all 
malignancies and 14% of deaths among head and neck 
neoplasms [10].
Histopathological types and anatomical location
As we mentioned before, the WHO classification di-
stinguishes 32 histopathological types, of which 23 types 
85–90% of all salivary gland neoplasms [12–13]. In the Po-
lish population, benign neoplasms constitute 79–85% of 
all neoplasm [5]. Benign neoplasms constitute 79–85% of 
salivary gland neoplasms [1, 12]. Major differences in the 
incidence of the particular histopathological types are in 
some measure caused by heterogenic reports in different 
countries. For example, in the population of Great Britain 
the majority of cancers are squamous cell carcinoma (17%) 
while muco-epidermoid carcinoma constitutes only 2.1% 
of salivary gland neoplasms [5, 15]. In the 1950s in the US 
population the most dominant was lymphoepithelial can-
cer, which accounted for as much as 25% of cases [5]. In 
most regions, there are two dominant histopathological 
types: among malignancies it is mucoepidermoid cancer 
and epithelioma adenoides cysticum while pleomorphic 
adenoma and Warthin’s tumor account for most cases of 
benign cancers [16–19].
Studies on the Polish population show that among be-
nign neoplasms, dominant are pleomorphic adenoma and 
Warthin’s tumor. The incidence of the former was, according 
to different authors, 63–75% and of the latter — 23.5–29% 
[1, 14, 20]. In the case of malignant neoplasms, the most 
common is epithelioma adenoides cysticum (23–25%), mu-
coepidermoid carcinoma (14–27%) and adenocarcinoma 
(14–22%). Less common is lymphoma (about 10%) and 
squamous cell carcinoma (6–14%). As we mentioned before, 
the percentage of female and male patients with salivary 
gland neoplasms is similar, whereby among patients with 
non-malignant neoplasms there is a slight prevalence of 
women [1, 20]. Studies based on data coming from care 
units operating salivary gland neoplasms show that the 
average age for benign neoplasms is about 10 years lower 
than for malignant neoplasms (50 and 60 years of age re-
spectively). Survival data concerning the British population 
show that lobular carcinoma has the best prognosis (5-OS 
97%), followed by mucoepidermoid carcinoma (5-OS 81%) 
and epithelioma adenoides cysticum (5-OS 80%). The worst 
prognoses are reported for adenocarcinoma (5-OS 50%) [11].
Boukheris et al. (29) compared the incidence of large 
salivary gland neoplasms in the American population ac-
cording to the sex and age of 6391 patients. Among men 
Figure 1. The raw factors for new cases of the parotid gland neoplasms in individual provinces (blue color) and the rest of the large salivary glands 
(red color) in the years of 2004–2014. Own study based on the KRN database
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with the most common neoplasms, a more frequently oc-
curring cancer was squamous cell carcinoma (20% with 
men and 8% with women). The median age of patients 
with squamous cell carcinoma was also significantly higher 
than the age of those with other types of neoplasm (72 
vs 63 years) [21]. Survival data for the British population 
show the best prognosis for lobular cancer (5-OS 97%). The 
worst prognosis was for adenocarcinoma (5-OS 50%) [11]. 
Similarly, in the Dutch population the best prognosis was 
for lobular cancer (5-year relative survival was 97% and the 
worst was for adenocarcinoma (54%) and squamous cell 
carcinoma (46%)) [29].
Studies of the Polish population show that salivary gland 
neoplasms are most often located in the parotid (77–82%) 
and sub-mandbular gland (11–12%). Less frequently the 
neoplasms are situated in small salivary glands (6–11%) 
[1, 10, 14, 20]. These data are in accordance with analyses 
from other countries. In a Brazilian study, the percentage of 
the parotid gland neoplasms was 69.5%; for the sub-mandi-
bular location it was 16% and in small glands it was 15% [22]. 
In an Iranian study in turn, 63% developed in the parotid 
gland, 23% were in the sub-mandibular region and 14% 
were located in small salivary glands [23]. Data coming from 
an African study, however, reveal a much higher occurrence 
of small salivary gland neoplasms (41.8–57.6%) [24–26]. 
Studies of the Polish population showed that in the parotid 
and sub-mandibular gland the dominant neoplasms were 
benign compared to malignant (82% and 71% respectively), 
and in the case of small salivary glands benign neoplasms 
occur only slightly more frequently (54 vs 46%) [14]. 
Studies of the Polish population show that the majority 
of patients are diagnosed as stage III (80%) (14). 11 (10%) 
of the cases were stage T4. 8 (7%) cases were qualified as 
T2 and 3 cases (3%) as T1 [14]. Data from the Dutch popu-
lation show that among men there is a similar percentage 
of patients at early stages of advancement (stage I, II and III, 
IV were 46 and 47.5% respectively). Female patients were 
most often those presenting early stages of advancement 
(stage I, II — 2.1%, stage III, IV — 31.6%) [29].
Trends of incidence and deaths
KRN data analysis from the last 15 years reveals a similar 
incidence rate for salivary gland neoplasms with a slight 
increase of incidence in the past two years, which may, 
however, be connected with increased reporting of that 
incidence [10]. Men account for a slim majority (51–62%). 
2014 was an exception, though, where the rate was higher 
for women (54). The highest incidence concerned the pa-
rotid gland, although there has been a slight growth in the 
last years (66% in 2000, 78% in 2014) [10] (Fig. 2, 3).
In the last few years there has been a minor increase in 
deaths from 158 in 2000 to 230 in 2014. The majority of deaths 
concerned men (52–66%). Deaths occurred mostly in the case 
of neoplasms located in the parotid gland (57–73%) and, like 
with the morbidity rate, there has been an insignificant rising 
tendency from 57% in 2000 to 73% in 2014 (Fig. 4, 5). 
Studies of world literature show a slight increase of 
the number of cases in the last few years (1990–2005). In a 
large study by DAHANCA, the raw factor for morbidity was 
1.1/100 000 and has been exhibiting a rising tendency in 
the last few years (1990–2005).
Similarly, there has been a small growth in the Chinese 
and British population [11, 28]. On the other hand, in the 
Dutch and Swedish population the incidence has been sta-
ble [21, 29, 30]. As was mentioned before, over the previous 
25 years, the percentage of US patients with salivary gland 
neoplasms has grown significantly (from 0.1% to 1%) [2].
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Figure 2. The incidence rate of salivary gland neoplasms in the years 2000–2014 including the site. P – parotid gland, O – other. Own study based 
on KRN data
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Figure 3. The incidence rate of salivary gland neoplasms in the years 2000–2014 according to sex. M – men, F – women. Own study based on KRN 
data
Figure 4. Deaths due to salivary gland cancer in the years 2000–2014 according to site. P –parotid gland, O – other. Own study based on KRN data
Figure 5. Deaths due to salivary gland cancer in the years 2000–2014 according to sex. M – men, F – women. Own study based on KRN data
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The US data show a constant level of survival at 68% 
[11]. On the other hand, the British data show a small im-
provement of survival [11]. In the periods 1994–2003 and 
2004–2013, 5-OS improved by 5% and 10-OS — by almost 
6% [11]. Dutch data, on the other hand, reveal slightly poorer 
survival [29]. Assuming that the relative co-efficient of su-
rvival in the years 1989–1993 was 1, in the years 1994–1998 
it was 0.97 and in the years 2007–2010 it was 0.84. In the 
years 1999–2002 and 2003 there was a minor improvement 
of survival. RER (Relative Excessive Risk of Dying) was 1.1 and 
1.03 respectively during that period [29]. The analysis of the 
RARECARE database shows that survival data are close to 
those from the previous years [7].The percentage of 1- and 
5-year survival of patients treated in the years 1995–1999 
was 87 and 69% respectively. For men, the values were 84 
and 60% and for women they were 91 and 80%. As in the 
years 2000–2002, younger patients and the Western Euro-
pean population had a better outlook [7].
Conclusion
Epidemiological data show that salivary gland cancer 
both in the global population as well as in the Polish po-
pulation is a rare head and neck cancer, and it occurs sligh-
tly more often in women. The most frequently occurring 
salivary gland neoplasm is parotid gland cancer. Salivary 
gland neoplasms are histologically a highly heterogeneous 
group differing in the frequency of occurrence, course and 
prognosis. In the last few years, the number of new cases 
has been roughly similar with a slightly rising tendency. 
The percentage of deaths has stayed on the same level in 
the said period. Women as well as patients with lobular and 
parotid gland cancer have a better outlook.
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